Understanding the RSV vaccines’ safety and efficacy will help when counseling a patient who is vaccine hesitant. During phase 3 clinical trials for Abrysvo, a single dose was 84.4% effective at preventing RSV-associated LRTD across 2 seasons.7Clinical trials for Arexvy demonstrated a 74.5% eff...
ACIP seems rightly sensitive to the consideration of individualized decision-making, taking into consideration other factors we’ve come to understand about vaccine literacy, uptake, hesitancy, and carefully listening to patient concerns during the COVID-19 pandemic and now-endemic experience as health ...